PTC Therapeutics, Inc. (PTCT) Operating margin 2016–2025
PTC Therapeutics, Inc. (PTCT) operating margin by fiscal year — reported operating income divided by reported revenue.
50.1%FY2025 · since FY2016: -159.7% → 50.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 50.1% | +87.6 pp |
| FY2024 | -37.5% | +9.4 pp |
| FY2023 | -46.9% | +17.2 pp |
| FY2022 | -64.0% | +5.5 pp |
| FY2021 | -69.5% | +43.9 pp |
| FY2020 | -113.4% | -34.8 pp |
| FY2019 | -78.6% | -34.9 pp |
| FY2018 | -43.7% | -10.6 pp |
| FY2017 | -33.1% | +126.6 pp |
| FY2016 | -159.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTCT financial trends
PTCT RevenuePTCT Net incomePTCT Net marginPTCT Gross profitPTCT Gross marginPTCT Operating incomePTCT Operating cash flowPTCT Free cash flowPTCT Capital expendituresPTCT Return on equityPTCT Stock buybacksPTCT Dividends paidPTCT Total assetsPTCT Total liabilitiesPTCT Shareholders’ equityPTCT overview →